What class of drugs does Ensifentrine belong to?

Ohtuvayre (Ensifentrine)-Ensifentine Inhalation Suspension is a new inhaled therapeutic drug mainly used to treat chronic obstructive pulmonary disease (COPD) in adults. From the perspective of drug classification, exefentine is a dual phosphodiesterase inhibitor (PDE3/PDE4 inhibitor), which has dual bronchodilator and anti-inflammatory effects. Unlike traditional bronchodilator drugs such as β2-receptor agonists and anticholinergic drugs, exefentine regulates the levels of intracellular cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) to achieve multi-target synergistic treatment. It is an innovative drug that has received widespread attention in the treatment of respiratory diseases in recent years.

As a non-hormonal drug, exefentine does not contain glucocorticoids, so it is suitable for patients with COPD who have poor sensitivity to steroids or cannot tolerate long-term steroid therapy. Its mechanism of action can be divided into two aspects: first, PDE3 inhibition, which mainly promotes the relaxation of bronchial smooth muscle, quickly relieves airway spasm, and achieves bronchodilation; second, PDE4 inhibition, by reducing the activity level of inflammatory cells such as eosinophils and macrophages, inhibits chronic airway inflammatory reactions, and helps to control disease activity in the long term. This combination of dual mechanisms is a distinctive feature that distinguishes Ensefentin from other inhaled drugs.

It is worth noting thatPDE4 inhibitors have representative drugs such as Roflumilast (Roflumilast) in the history of drug development, but their use is often limited by high gastrointestinal adverse reactions after oral administration. Exefantine is administered by inhalation, which can act locally on the lungs and reduce systemic exposure, thereby significantly reducing the incidence of side effects while maintaining efficacy, and improving patient compliance and safety.

Reference materials:https://www.drugs.com/monograph/ensifentrine.html